Rigel Pharmaceuticals, Inc. (RIGL) Q1 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Greetings and welcome to Rigel Pharmaceutical's financial conference call for the first quarter, 2026. At this time, all participants are in a listen-only mode. A brief question and answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. As a reminder, this conference is being recorded. It is now my pleasure to introduce our speaker, Ray Furey, Rigel's Executive Vice President, General Counsel, and Corporate Secretary. Thank you. Mr. Furey, you may begin. Welcome to our first quarter of 2026 financial results business update conference call. The financial press release for the first quarter of 2026 was issued a short while ago. section of our investor relations site on Rytle.com. As a reminder, during today's call, we may make forward-looking statements regarding our financial outlook and our plans and timing for regulatory product development. These statements are subject to risks and uncertainties that may cause actual results to differ from those forecasted. A description of these risks can be found in our most recent annual report, Form 10-K, for the year ended December 31st, 2025, on file with the SEC, and subsequent filings with the SEC, including the Q1 quarterly report on Form 10-Q with the SEC. Any forward-looking statements are made only as of today's date, and we undertake no obligation to update these forward-looking statements. our circumstances. At this time, I'd like to turn the call over to our President and Chief Executive Officer, Raul Rodriguez. Raul? Thank you, Ray, and thank you for joining us today. Also joining me on the call today are Dave Santos, our Chief Commercial Officer, Lisa Royker, our Chief Medical Officer, and Dean Shorno,...